Immune modulation by cytokines in the treatment of opportunistic infections

Current Opinion in Infectious Diseases

Volumn 10, Issue 4, 1997, Pages 275-280

  Poynton, Christopher H ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

CANDIDIASIS; CELL INTERACTION; EFFECTOR CELL; HELPER CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; MYCOSIS; OPPORTUNISTIC INFECTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030877793     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199708000-00005     Document Type: Review

References (54)

1. Donowitz GR: Fever in the compromised host. Infect Dis Clin North Am 1996, 10:129-148.
2. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad II et al: Flucunazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Ann J Med 1996, 101:170-176.
3. Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996, 100:617-623. In this large (427 participants) study, the non C. albicans species emerged as important and frequent pathogens particularly in patients on antifungal prophylaxis.
4. Girmenia C, Martino P, Cassone A: Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies. Blood 1996, 87:838-839.
5. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE: Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus infected patients. J Infect Dis 1996, 173:219-225.
6. Uzun O, Anaissie EJ: Antifungal prophylaxis in patients with hematologic malignancies. A reappraisal. Blood 1995, 86:2063-2072.
7. Klein NC, Cunha BA: New antifungal drugs for pulmonary mycoses. Chest 1996, 110:525-532. A review of the newer antifungal agents, including itraconazole.
8. Herbrecht R: The changing epidemiology of fungal infections: are the lipid forms of amphotericin B an advance? Eur J Haematol 1996, (Suppl 57):12-17.
9. Armstrong D: Overview of invasive fungal infections and clinical presentations. Baillières Clin Infect Dis 1995, 2:17-24.
10. Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ: Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethazone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996, 34:63-69. Steroids are widely used in chemotherapy and are associated with the development of deep-seated fungal infection. In this paper, the authors assessed various monocyte functions after exposure to dexamethazone, and corrected them with GM-CSF and IFNs-γ.
11. Ellis ME, Halim MA, Spence D, Ernst P, Clink H, Kalin H, Baillie F, Greer W: Systemic ampohotericin B verus fluconazole in the management of antibiotic-resistant neutropenic fever - preliminary observations from a pilot, exploratory study. J Infect 1995, 30:141-146.
12. Mencacci A, Torosantacci A, Spaccapelo R, Romani L, Bistoni F, Cassone A: A manno protein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production and anticandidal protection in mice. Infect Immun 1994, 62:5353-5360.
13. Romagnani S: TH1 and TH2 in human diseases. Clin Immunol Immunopathol 1996, 80:225-235. A magnificant review of the Th1/Th2 model of cytokine profiles applied to a whole range of human diseases. Essential reading for those interested in modulating immunity to infection of cancer.
14. Ehrlich R: Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation, Immunol Res 1995, 14:77-97.
15. Lawson RD, Gentry LO, Bodey GP, Keating MJ, Smith TL: A randomized study of tobramycin plus hicarcillin, tobramycin plus cephalothin and ticarcillin, or tobramcyin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. Am J Med Sci 1984, 287:16-23.
16. Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, Mueller P, Huhn D, Masch R, Siegert W: Randomized, double-blind, placebo controlled phase II study of recombinant human granulocyte-macrophage colony stimulating factor as adjunct to induction treatment of high grade malignant Hodgkin's lymphoma. Blood 1993, 82:2329-2339.
17. Terpestra W, Löwenberg B: Application of myeloid growth factors in the treatment of acute myeloid leukaemia. Leukaemia 1997, 11:315-327. A good overall review of the current use G-CSF and GM-CSF in acute myeloid leukaemia. Neutropenia, leukaemia stimulation, toxicity and differentiation therapy are all covered.
18. Rowe JM, Liesveld JL: Hematopoietic growth factors in acute leukaemia. Leukaemia 1997, 11:328-341. This review focuses more on the immunological effects of growth factors, such as enhancement of antimicrobial function, as well as novel approaches to the use of cytokines as anti-tumour agents.
19. Anaissie EJ, Vartivarian S, Bodey GP, Legrand C, Kantarjian H, Abi-Said D, Karl C, Vadhan-Rai S: Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony stimulating factor (Escherichia coil-derived) in cancer patients with fever and neutropenia. Ann J Med 1996, 100:17-23.
20. Hussein AM, Elkordy M, Peters WP: The use of growth factors with antibiotics in the setting of neutropenic fever. Am J Med 1996, 100:15-16.
21. Hartung T, Döcke WD, Gantner F, Krieger G, Sauer A, Stevens P, Volk HD, Wendel A: Effects of granulocyte colony-stimulating factor treatment on ex-vivo blood cytokine response in human volunteers. Blood 1995, 85:2482-2489.
22. Aoki Y, Horomatsu K, Hotta T, Kobayashi N, Saito H, lgarashi H, Miko Y, Yoshikai Y: Protective effect of granulocyte colony-stimulating factor against T-cell mediated lethal shock triggered by super-antigens. Blood 1995, 86:1420-1427.
23. Pan L, Delmonte J, Jalonen CK, Ferrara JL: Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995, 86:4422-4429.
24. Pucetti P, Romani L, Bistoni F: A Th1-Th2-like switch in candidiasis: new perspectives in therapy. Trends Microbiol 1995, 3:237-240.
25. Romagnani S: Induction of Th1 and Th2 response: a key role for the 'natural' immune response? Immunol Today 1992, 13:379-381.
26. Cenci E, Mencacci A, Spaccapelo R, Tonnetti L, Mosci P, Enssle KH, Puccetti P, Romani L, Bistoni F: T helper cell type 1 (Th1) and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis 1995, 171:1279-1288.
27. + Th1 and Th2 cells by blood dendritic cells. Scand J Immunol 1996, 43:646-651.
28. Calderone R, Sturtevant J: Macrophage interactions with Candida. Immunol Series 1994, 60:505-515.
29. Fresno M, Kopf M, Rivas L: Cytokines and infectious diseases, Immunol Today 1997, 18:56-58. Although this is reporting a recent conference, it contains many extremely valuable points on cytokines in infectious diseases, and will be valuable in formulating cytokine directive therapy.
30. Jones-Casson J, Vazquez-Torres A, Van der Heyde HC, Warner T, Wagner RD, Balish E: Gamma delta T-cell-induced nitric oxide production enhances resistance to mucosal candidiasis. Nature Med 1995, 1:552-557.
31. Kelso A: Th1 and Th2 subsets. Paradigms lost? Immunol Today 1995, 16:374-379.
32. Gause WC, Halvorson MJ, Lu P, Greenwald R, Linsley P, Urban JF, Finkelman FD: The function of co-stimulatory molecules and the development of IL-4-producing cells, Immunol Today 1997, 18:115-120. A very up-to-date review of the signals involved in a TH2 response.
33. Spaccapelo R, Romani L, Tonnetti L, Cenci E, Mencacci A, Del Sero G, Tognellini R, Reed SG, Puccetti P, Bistoni F: TGF-β is important in determining the in-vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J Immunol 1995, 155:1349-1360.
34. Openshaw P, Murphy EE, Hosken NA, Maino V, Davis K, Murphy K, O'Garra A: Heterogeneity of intracellular cytokine synthesis at the single cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 1995, 182:1357-1367.
35. Romani L, Mencacci A, Tonnetti L, Spaccapelo R, Cenci E, Puccetti P, Wolf SF, Bistoni F: I.L-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol 1994, 153:5167-5175.
36. + T-cells. Ann Rev Immunol 1994, 12:635-674.
37. Casadevall A: Antibody immunity and invasive fungal infections. Infect Immun 1995, 63:4211-4218.
38. Ffeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K: Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995, 181:1569-1574.
39. Kumar V, Bhardwaj V, Soares L, Alexander J, Selte A, Sercarz E: Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T-cells. Proc Natl Acad Sci 1995, 92:9510-9514.
40. + T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med 1996, 183:1345-1355.
41. Windhagen A, Anderson DE, Carrizosa A, Williams RE, Hafler DA: IL-12 induces human T-cells secreting IL-10 with IFN gamma. J Immunol 1996, 157:1127-1131.
42. + thymocytes into functionally mature Th2 cells. Exogenous interleukin-12 is required for priming thymocytes to produce both Th1 cytokines and interleukin-10. Eur J Immunol 1996, 26:1083-1087.
43. Robey E, Allison JP: T-cell activations: integration of signals from the antigen receptor and co-stimulatory molecules, Immunol Today 1995, 16:305-362.
44. Peng X, Kasran A, Warmerdam PA, De Boer M, Ceuppens JL: Accessory signaling by CD40 for T-cell activation: induction of Th1 and Th2 cytokines in synergy with interleukin-12 for interferon gamma production. Eur J Immunol 1996, 26:1621-1627.
45. Romagnani S: Role for CD30 antigen in human T helper 2 type responses. Ciba Foundation Symposium 1996, 195:55-62.
46. Hamann D, Hilkens CM, Grogan JL, Lens SM, Kapsenberg ML, Yazdanbakhsh M, van Lier RA: CD30 expression does not discriminate between human Th-1 and Th-2-type cells. J Immunol 1996, 156:1387-1391.
47. Biancone L, Andres G, Ahn H, Um A, Dai C, Noelle R, Yagita H, De Martino C, Stamenkovic I: Distinct regulatory roles of lymphocyte costimulatory pathways on T helper type 2-mediated autoimmune diseases. J Exp Med 1996, 183:1473-1481.
48. Nelson RD, Shibata N, Podzorski RP, Herron MJ: Candida mannan: chemistry, suppression of cell-mediated immunity, and possible mechanisms of actions. Clin Microbiol 1991, 4:1-9.
49. Sweeney JF, Rosemurgy AS, Wei S, Djeu JY: Impaired polymorphonuclear leukocyte anticandidal function in injured adults with elevated Candida antigen titers. Arch Surg 1993, 128:40-45.
50. Lechner AJ, Lamprech KE, Potthoff LH, Tredway TL, Matuschak GM: Recombinant QM-CSF reduces lung injury and mortality during neutropenic Candida sepsis. Am J Physiol 1994, 266:L561-568
51. Hill AD, Naama H, Shou J, Calvano SE, Daly JM: Antimicrobial effects of granulocyte-macrophage colony-stimulating factor in protein-energy malnutrition. Arch Surg 1995, 130:1273-1277.
52. Hague RA, Eastham EJ, Lee RE, Cant AJ: Resolution of hepatic abscess after interferon gamma in chronic granulomatous disease. Arch Dis Childhood 1993, 69:443-445.
53. Kullberg B-J, van't Wout JW, Hoogstraten C, van Furth R: Recombinant interferon gamma enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 1993, 168:436-443.
54. + T-cells, analysed at the single cell level. J Exp Med 1996, 184:473-483.